Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

GE Healthcare and Cellular Dynamics International Agree to Sublicense for Cellular Assay Patents

Published: Wednesday, December 19, 2012
Last Updated: Wednesday, December 19, 2012
Bookmark and Share
Companies have announced that GE Healthcare has licensed CDI to develop, manufacture and sell cellular assays and models derived from iPS cells for use in drug discovery and toxicity screening.

The agreement follows the recent announcement that GE Healthcare has expanded its license with Geron to obtain exclusive global rights to Geron’s intellectual property and know-how for the development and sale of cellular assays derived from iPS cells. Financial terms were not disclosed.

As the worldwide pharmaceutical industry seeks to reduce drug development costs and bring more effective, safer drugs to market, the availability of more biologically relevant and predictive cell models becomes increasingly important. GE Healthcare is pioneering the development of human cell-based assays and models for use in drug discovery and predictive toxicity screening. In 2010 the company launched Cytiva™ cardiomyocytes (human heart cells), stem cell-based assays that are already helping pharmaceutical companies identify drug candidates that show toxic effects much earlier in the discovery process.

Cellular Dynamics develops, manufactures and sells human cells based on iPS cell technology and currently offers iCell® Cardiomyocytes, iCell Neurons (brain cells), iCell Endothelial Cells (blood vessel cells) and iCell Hepatocytes (liver cells). CDI has also launched MyCell™ Services, a custom cell manufacturing service that leverages the ability of iPS cell technology to make stem cells or terminal cells from any individual, including those with diseases of interest to pharmaceutical companies and academic scientists.

Dr Amr Abid, General Manager, Cell Technologies, GE Healthcare Life Sciences, said, “We believe it is important that stem cell-based assays are available to researchers so that progress can be made in drug discovery; clarity and freedom to operate is fundamental to advancing the use of such assays. Our recently extended agreement with Geron provided the foundation for the type of agreement we are announcing today. GE Healthcare believes that such agreements are the next step to enabling the wider industry to benefit from the use of this key intellectual property without violating patent rights. We are delighted that Cellular Dynamics International is the first company to work with us to bring greater clarity to the marketplace.”

Bob Palay, CEO of Cellular Dynamics International, added,  “CDI’s mission is to provide human cell-based research and drug discovery tools that enhance scientists’ ability to better understand human biology, increase efficiency of the discovery process and ultimately improve human healthcare. The IP space surrounding stem cell technology is complex. With the licensing of the GE-Geron intellectual property portfolio, CDI now has more than 700 licensed or owned patents and patent applications. We have built our IP portfolio intending to ensure broad freedom to operate and to offer customers products that they can use with confidence and the knowledge that their subsequent discoveries are protected by this IP portfolio.”

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

The Hamner Institutes and Cellular Dynamics Collaborate
The parties will develop predictive in vitro screening assays for chemical, environmental and pharmaceutical toxicology assessments.
Monday, December 09, 2013
Cellular Dynamics International and Roche Transition Early Access
Collaboration into a standard supply agreement ahead of schedule.
Saturday, March 26, 2011
CDI, ACEA and Roche Cooperate to Evaluate iCell Cardiomyocytes on the xCELLigence System
The partnership will bring early and accurate prediction of potential cardiotoxic side effects to the drug discovery process.
Tuesday, September 21, 2010
Cellular Dynamics Partners with iPS Academia Japan to In-License Seminal iPS Cell Patent Portfolio
Companies announce a nonexclusive licensing agreement for the seminal iPSC patent portfolio arising out of the work of Dr. Shinya Yamanaka.
Monday, May 10, 2010
Cellular Dynamics Raises $40.6 MM to Revolutionize Pharma Drug Research
The financing enables the company to increase production capacity for its iCell™ Cardiomyocytes and to launch additional human tissue cell products.
Thursday, April 29, 2010
CDI’s iCell™ Cardiomyocytes Named to MIT Technology Review’s Annual 10 Emerging Technologies List
iCell Cardiomyocytes are first human IPSC-derived cell type launched for high throughput drug discovery and toxicity testing.
Friday, April 23, 2010
Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing
Greater than 90 percent cell type purification enabled through exclusively licensed technology.
Friday, July 17, 2009
Cellular Dynamics International and Roche Expand Existing Cardiotoxicity Screening Agreement
The two-year collaboration aims to enhance drug safety testing in order to bring promising therapies to patients.
Thursday, July 02, 2009
Cellular Dynamics International Licenses Key Patent Portfolio Surrounding Cardiovascular Progenitor Cells
The exclusive license covers differentiation of stem cells into all cell types of the human heart.
Wednesday, June 03, 2009
Scientific News
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Study Finds Key Regulator in Pulmonary Fibrosis
Researchers identify an enzyme that could open the way to therpies for chronic fatal lung disease.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Ovarian Cancer Insight
Study showed tumours release cytokines to attract macrophages, which secrete growth factors that in turn promote tumour growth.
Substance Can Potentially Postpone Aging
Researchers bridge the gap between two main aging theories - repairs to the DNA and poor functioning mitochondria.
Untangling Cause Of Memory Loss In Neurodegenerative Diseases
NIH-funded mouse study identifies a possible therapeutic target for a family of disorders.
New Model for Understanding Human Myeloma
Researchers develop mouse model where mice carry six human genes involved in human tumour growth.
Preventing Alzheimer's in Mice
Researchers have prevented the Alzheimer’s development in mice by using a virus delivery system to transport a specific gene into the brain.
New Platform for Roundworms Could Speed Up Drug Delivery
Researchers have developed a large-scale in vitro drug discovery platform that could speed up scientific research.
"Junk" DNA Critical for Heart Function
Loss of noncoding elements of genome, known as enhancers, results in abnormalities of heart functions.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos